4.7 Article

Design, synthesis and evaluation of phenylthiazole and phenylthiophene pyrimidindiamine derivatives targeting the bacterial membrane

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 190, Issue -, Pages -

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112141

Keywords

Antibacterial activity; Phenylthiazole; Phenylthiophene pyrimidindiamine; Membrane damage

Funding

  1. National Key R&D Program of China [2018YFA0507000]
  2. National Natural Science Foundation of China [81773204, 81673304, 81973160]
  3. Shanghai Municipal Education Commission [2017-01-07-00-05-E00011]
  4. Shenzhen Municipal Government of China [KQTD20170810160226082]
  5. Shanghai Natural Science Foundation [18ZR1431700]
  6. ECNU Public Platform for Innovation [011]

Ask authors/readers for more resources

As the continuous rise in the incidence of antibiotic resistance, it is urgent to develop novel chemical scaffolds with antibacterial activities to control the spread of resistance to conventional antibiotics. In this study, a series of phenylthiazole and phenylthiophene pyrimidindiamine derivatives were designed and synthesized by modifying the hit compound (N-2-isobutyl-N-4-((4-methyl-2-phenylthiazol-5-yl) methyl) pyrimidine-2,4-diamine) and their antibacterial activities were evaluated both in vitro and in vivo. Among the tested compounds, compound 14g (N4-((5-(3-bromophenyl)thiophen-2-yl)-methyl)N-2-isobutylpyrimidine-2,4-diamine) displayed the best antibacterial activities, which was not only capable of inhibiting E. coil and S. aureus growth at concentrations as low as 2 and 3 mu g/mL in vitro, but also efficacious in a mice model of bacteremia in vivo. Unlike conventional antibiotics, compound 14g was elucidated to mainly destroy the bacterial cell membrane, with the dissipation of membrane potential and leakage of contents, ultimately leading to cell death. The destruction of cell structure is challenging to induce bacterial resistance, which suggested that compound 14g may be a kind of promising alternatives to antibiotics against bacteria. (C) 2020 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie, Dongxia Huang, Pan Hu, Miaoran Zhou, Lin Zhang, Qiansen Zhang, Peili Wang, Xin Wang, Guixue Wang, Huangan Wu, Cili Zhou, Yihua Chen, Mingyao Liu, Zhengfang Yi, Zhenliang Sun

Summary: Researchers have identified a small molecule compound named WK500B that can block the inhibition of BCL6, reactivate target genes, kill DLBCL cells, and display strong anti-tumor effects in animal models. Therefore, WK500B holds promise as an effective orally available therapeutic agent for DLBCL.

CANCER LETTERS (2022)

Article Chemistry, Medicinal

Discovery of 2-Amino-3-cyanothiophene Derivatives as PotentSTAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis

Wangrui Jin, Tao Zhang, Wenbo Zhou, Peng He, Yue Sun, Shijia Hu, Huang Chen, Xinglong Ma, Yangrui Peng, Zhengfang Yi, Mingyao Liu, Yihua Chen

Summary: Osteosarcoma, a common malignant bone tumor, has seen little progress in treatment and clinical outcomes due to its heterogeneity and high mutation rate. Targeting STAT3 has shown potential as a feasible therapeutic strategy for osteosarcoma.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Novel orthodiphenyl five-member N-heteroaromatic compounds as potent anticancer cell agents

Shijia Hu, Yunqi Li, Weiqiong Kan, Tingting Ding, Haijun Gu, Ting Zhang, Zhengfang Yi, Yihua Chen

Summary: A series of diphenyl-N-heteroaromatic compounds were synthesized and evaluated for their anticancer activities. Compound 4b and 4c, optimized from favorable compound 4a, showed more potent antimigratory and antiproliferative activities. The results suggest that compounds 4b and 4c with 1,2,3-triazole scaffold may have potential as potent anticancer agents.

MEDICINAL CHEMISTRY RESEARCH (2022)

Editorial Material Oncology

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Dazhao Mi, Yuzhan Li, Yihua Chen

Summary: This article provides an overview of the role of SHP2 protein tyrosine phosphatase in cancer-related signaling pathways, as well as the therapeutic strategies targeting SHP2, including PTP inhibitors, allosteric inhibitors, and SHP2-targeting PROTACs. The benefits and limitations of these strategies are discussed. The opportunities and challenges of targeting SHP2 are also presented.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2023)

Article Oncology

A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer

Luzhen Wang, Dazhao Mi, Jinhui Hu, Wenjing Liu, Yi Zhang, Chunyan Wang, Yihua Chen, Ceshi Chen

Summary: TNBC is a highly malignant tumor with poor prognosis. This study identified DZ-514 as a potent compound with high toxicity against TNBC cells, independent of BCL6 inhibition. DZ-514 reduced cell viability, inhibited cell cycle progression, and induced caspase-independent cell death in TNBC cells. Importantly, DZ-514-induced vacuoles were derived from macropinosomes rather than autophagosomes.

CANCER LETTERS (2023)

Article Oncology

Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

Huang Chen, Wenbo Zhou, Aiwu Bian, Qiansen Zhang, Ying Miao, Xuan Yin, Jiangnan Ye, Shifen Xu, Chaowen Ti, Zhenliang Sun, Jianghua Zheng, Yihua Chen, Mingyao Liu, Zhengfang Yi

Summary: This study identifies a novel drug called WB436B as a selective STAT3 inhibitor for the treatment of pancreatic cancer. WB436B effectively inhibits tumor growth and metastasis, providing hope for the treatment of pancreatic cancer.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF? signaling pathway

Yuzhu Zhang, Jing Chen, Dazhao Mi, Jun Ling, Huachao Li, Peng He, Ning Liu, Qianjun Chen, Yihua Chen, Luqi Huang

Summary: In this study, the natural product harmine was identified as a potential compound for treating triple-negative breast cancer (TNBC). The compound was further modified and optimized to obtain a lead compound, YH677, which showed strong anti-proliferative and anti-migratory effects in vitro and suppressed breast cancer growth and metastasis in vivo. Mechanistic studies revealed that YH677 inhibits the expansion of cancer stem cells by regulating the TGF beta/Smad signaling pathway.

CANCER LETTERS (2023)

Correction Oncology

Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF beta signaling pathway (vol 560, 216142, 2023)

Yuzhu Zhang, Jing Chen, Dazhao Mi, Jun Ling, Huachao Li, Peng He, Ning Liu, Qianjun Chen, Yihua Chen, Luqi Huang

CANCER LETTERS (2023)

Article Chemistry, Medicinal

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance

Peng He, Juanjuan Feng, Xinting Xia, Yue Sun, Jia He, Tian Guan, Yangrui Peng, Xueli Zhang, Mingyao Liu, Xiufeng Pang, Yihua Chen

Summary: HP661 is a highly effective OXPHOS inhibitor that can inhibit mitochondrial oxygen consumption in high OXPHOS lung cancer cells. It also shows significant sensitivity in MEK inhibitor-resistant lung cancer cells and has therapeutic efficacy against high OXPHOS lung cancer.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer

Jia He, Luzhen Wang, DaZhao Mi, Tian Guan, Wenjing Liu, Peng He, Haijun Gu, Yuzhan Li, Yangrui Peng, Ai-Qun Jia, Ceshi Chen, Yihua Chen

Summary: JH530 is a drug that can induce cell death in triple-negative breast cancer cells and has shown significant suppression of tumor growth in vitro and in vivo.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Medicine, Research & Experimental

Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma

Yali Wang, Wenbo Zhou, Jianfeng Chen, Jinghong Chen, Peng Deng, Huang Chen, Yichen Sun, Zhaoliang Yu, Diwen Pang, Lizhen Liu, Peili Wang, Jing Han Hong, Bin Tean Teh, Huiqiang Huang, Wenyu Li, Zhengfang Yi, Soon Thye Lim, Yihua Chen, Choon Kiat Ong, Mingyao Liu, Jing Tan

Summary: A new and potent STAT3 inhibitor, WB737, has been developed as a potential therapeutic option for NKTL. It selectively inhibits NKTL with STAT3-activating mutations and suppresses both canonical and noncanonical STAT3 signaling. WB737 shows significant antitumor effects with minimal toxicity, providing a promising strategy for treating NKTL patients.

MEDCOMM (2023)

Article Medicine, Research & Experimental

A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia

Lin Zhang, Min Wu, Weikai Guo, Shuangshuang Zhu, Shen Li, Shiyi Lv, Yan Li, Layang Liu, Yajing Xing, Huang Chen, Mingyao Liu, Shihong Peng, Yihua Chen, Zhengfang Yi

Summary: BCL6 is a transcriptional repressor that plays a role in immune cell differentiation, DNA damage repair, cell cycle, and apoptosis. A small molecule compound called WK499 has been identified as a inhibitor of BCL6, which inhibits the proliferation of AML cells and enhances the sensitivity of AML to chemotherapy. WK499 achieves this by disrupting the interactions between BCL6 and its corepressor proteins, leading to changes in downstream genes and induction of cell cycle arrest and apoptosis.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Review Chemistry, Medicinal

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design

Dazhao Mi, Yuzhan Li, Haijun Gu, Yan Li, Yihua Chen

Summary: Proteolysis-targeting chimeras (PROTACs) have gained significant attention as an emerging modality in drug discovery. After over 20 years of development, accumulated studies have shown that PROTACs offer unique advantages over traditional therapy in terms of target scope, efficacy, and overcoming drug resistance. However, the limited availability of E3 ligases, essential components of PROTACs, poses a challenge for their design. This review provides a systematic summary of the current status of E3 ligases and corresponding ligands for PROTACs design, including their discovery history, design principles, application benefits, and potential limitations. The prospects and future directions in this field are also briefly discussed.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Review Chemistry, Medicinal

Recent advances in small molecule and peptide inhibitors of glucose-regulated protein 78 for cancer therapy

Weikai Guo, Manjie Wang, Zhengfan Yang, Danyang Liu, Borui Ma, Yanqun Zhao, Yihua Chen, Yanzhong Hu

Summary: This article comprehensively reviews the structure, physiological functions, and recent progress of GRP78, and discusses the merits and demerits of GRP78 inhibitors as well as novel strategies for drug discovery targeting GRP78. The feasibility of PROTACs and covalent inhibition as new opportunities for targeted antitumor therapy are also explored.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment

Peng He, Ying Miao, Yue Sun, Aiwu Bian, Wangrui Jin, Jiangnan Ye, Huang Chen, Jia He, Yangrui Peng, Haijun Gu, Mingyao Liu, Zhengfang Yi, Yihua Chen

Summary: This study describes the design, synthesis, and structure-activity relationship studies of triaromatic heterocyclic derivatives as potent dual phosphorylation STAT3 inhibitors. The best compound 3h (HP590) was discovered with high inhibitory activity against p-Tyr(705) and p-Ser(727), resulting in the growth inhibition of gastric cancer both in vitro and in vivo.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection

Shuang Mei, Su Jiang, Yuting Wang, Han Jing, Peng Yang, Miao-Miao Niu, Jindong Li, Kai Yuan, Yan Zhang

Summary: This study identifies a dual-targeting peptide, AP-1, that effectively inhibits variants of concern (VOCs) of SARS-CoV-2 without impairing host cell viability. The findings suggest that AP-1 could be a promising broad-spectrum agent for treating emerging VOCs of SARS-CoV-2.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Discovery of proteolysis-targeting chimera targeting undruggable proteins using a covalent ligand screening approach

Hyeonjun Lee, Ju Yeon Lee, Hyunsoo Jang, Hye Young Cho, Minhee Kang, Sang Hyun Bae, Suin Kim, Eunji Kim, Jaebong Jang, Jin Young Kim, Young Ho Jeon

Summary: By using liquid chromatography-tandem mass spectrometry and nuclear magnetic resonance experiments, we identified new chemical moieties that bind to the target sites of the protein of interest, allowing for reversible binding and protein degradation. This method has the potential to expand the application of PROTAC technology.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

A pro-death autophagy-based nanoplatform for enhancing antitumour efficacy with improved immune responses

Yingying Li, Xiyou Du, Xinru Kong, Yuelin Fang, Zhijing He, Dongzhu Liu, Hang Wu, Jianbo Ji, Xiaoye Yang, Lei Ye, Guangxi Zhai

Summary: This study proposes a novel nanoplatform based on the autophagy cascade to overcome the obstacles in chemo-immunotherapy. The platform combines chemotherapy and starvation therapy to initiate pro-death autophagy and enhance antigen presentation, while also remodeling the immunosuppressive tumor microenvironment. Furthermore, the study discovers a new therapeutic direction for the respiration inhibitor 3-bromopyruvic acid (3BP) in cancer treatment. Overall, this study offers an opportunity to improve antitumor efficacy and boost immune responses.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER plus breast cancer

Bingsi Wang, Mingxu Ma, Yusen Dai, Pengfei Yu, Liang Ye, Wenyan Wang, Chunjie Sha, Huijie Yang, Yingjie Yang, Yunjing Zhu, Lin Dong, Shujuan Wei, Linlin Wang, Jingwei Tian, Hongbo Wang

Summary: Breast cancer is a common malignant tumor in women, and drug resistance remains a clinical challenge. In this study, a novel compound, G-5b, was developed with potent antagonistic and degradation activities comparable to the current drug fulvestrant. G-5b also showed improved stability and solubility. Mechanistically, G-5b engages the proteasome pathway to degrade ER, inhibiting the ER signaling pathway and inducing apoptosis and cell cycle arrest. In animal models, G-5b exhibited superior pharmacokinetics and pharmacodynamics properties. Overall, G-5b is a promising long-acting SERD worthy of further investigation and optimization.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents

Karoline B. Waitman, Larissa C. de Almeida, Marina C. Primi, Jorge A. E. G. Carlos, Claudia Ruiz, Thales Kronenberger, Stefan Laufer, Marcia Ines Goettert, Antti Poso, Sandra V. Vassiliades, Vinicius A. M. de Souza, Monica F. Z. J. Toledo, Neuza M. A. Hassimotto, Michael D. Cameron, Thomas D. Bannister, Leticia Costa-Lotufo, Joa o A. Machado-Neto, Mauricio T. Tavares, Roberto Parise-Filho

Summary: A series of hybrid inhibitors combining pharmacophores of known kinase inhibitors and benzohydroxamate HDAC inhibitors were synthesized and evaluated for their anticancer activity and pharmacokinetic properties. Compounds 4d-f exhibited promising cytotoxicity against hematological cells and moderate activity against solid tumor models. Compound 4d showed potent inhibition of multiple kinase targets and had stable interactions with HDAC and members of the JAK family. These compounds showed selective cytotoxicity with minimal effects on non-tumorigenic cells and favorable pharmacokinetic profiles.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Unexpected rearrangement of ivermectin in the synthesis of new derivatives with trypanocidal and antiplasmodial activities

Michal Sulik, Diana Fontinha, Dietmar Steverding, Szymon Sobczak, Michal Antoszczak, Miguel Prudencio, Adam Huczynski

Summary: This study describes the synthesis of the first-in-class ivermectin derivatives obtained through derivatization of the C13 position, along with the unexpected rearrangement of the macrolide ring. These derivatives show potential for antiparasitic activity and are important for the development of new antiparasitic agents.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Novel ligustilide derivatives target quorum sensing system LasR/LasB and relieve inflammatory response against Pseudomonas aeruginosa infection

Jun Liu, Qiu-Xian Chen, Wen-Fu Wu, Dong Wang, Si -Yu Zhao, Jia-Hao Li, Yi-Qun Chang, Shao-Gao Zeng, Jia-Yi Hu, Yu-Jie Li, Jia-Xin Du, Shu-Meng Jiao, Hai-Chuan Xiao, Qiang Zhang, Jun Xu, Jian-Fu Zhao, Hai -Bo Zhou, Yong-Heng Wang, Jian Zou, Ping-Hua Sun

Summary: A new anti-infective drug strategy has been discovered to attenuate virulence and modulate inflammation caused by drug-resistant Pseudomonas aeruginosa infections. Compound 5f inhibits biofilm formation, macrophage migration, and inflammatory response induced by P. aeruginosa, showing potential as a novel candidate against drug-resistant infections.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Design and synthesis of pterostilbene derivatives bearing triazole moiety that might treat DSS-induced colitis in mice through modulation of NF-KB/ MAPK signaling pathways

Liuzeng Chen, Ke Wang, Lingyun Wang, Wei Wang, Lifan Wang, Jia Li, Xiaohan Liu, Mengya Wang, Banfeng Ruan

Summary: In this study, a series of novel anti-inflammatory compounds were designed and synthesized based on the natural product pterostilbene skeleton. Among them, compound 8 showed the highest activity and exhibited its effects through inhibition of pro-inflammatory cytokines by blocking the NF-KB/MAPK signaling pathway. Compound 8 also demonstrated a good relieving effect on acute colitis in mice and showed good safety in acute toxicity experiments.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Discovery of 4-(N-dithiobenzyl piperazine)-1,8-naphthalimide as a potent multi-target antitumor agent with good efficacy, limited toxicity, and low resistance

Si-Min Liang, Gui-Bin Liang, Hui-Ling Wang, Hong Jiang, Xian-Li Ma, Jian-Hua Wei, Ri-Zhen Huang, Ye Zhang

Summary: A series of novel multi-target antitumor agents were designed, synthesized, and evaluated. Some compounds exhibited significant antitumor activity and one compound showed excellent efficacy, limited toxicity, and low resistance. Further mechanism studies revealed that the compound exerted antitumor effects through multiple pathways.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)